Kepler Capital Markets Analysts Give Novartis AG (NOVN) a CHF 88 Price Target
The firm currently has a buy rating on the stock. NOVN has been the subject of several other reports.
from Biotech News
The firm currently has a buy rating on the stock. NOVN has been the subject of several other reports.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments